Drug General Information |
Drug ID |
D02KLW
|
Former ID |
DNC005812
|
Drug Name |
DIZOCILPINE
|
Drug Type |
Small molecular drug
|
Indication |
Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63]
|
Terminated |
[1],
[2]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H15N
|
InChI |
InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3/t15-,16+/m1/s1
|
InChIKey |
LBOJYSIDWZQNJS-CVEARBPZSA-N
|
CAS Number |
CAS 77086-21-6
|
PubChem Compound ID |
|
PubChem Substance ID |
586326, 603151, 7979108, 10259226, 11111403, 11111404, 11466137, 11467257, 11485773, 16107416, 16180231, 26751971, 33503095, 47216999, 47217000, 47291334, 47291335, 47440489, 47736714, 47885615, 47959980, 47959981, 48259469, 48334731, 49698349, 50104646, 57395705, 77234575, 85787792, 85787950, 90341814, 103193630, 103939283, 104431219, 124750063, 124882687, 124882688, 131347199, 134343017, 135650617, 136080151, 137100768, 162009802, 162022805, 179151131, 198949394, 223366874, 223442356, 225082654, 226087978
|
Target and Pathway |
Target(s) |
NMDA receptor subunit NR1 |
Target Info |
Inhibitor |
[3]
|
Adenosine A3 receptor |
Target Info |
Inhibitor |
[4]
|
Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Inhibitor |
[3]
|
Glutamate [NMDA] receptor subunit epsilon 1 |
Target Info |
Inhibitor |
[3]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Circadian entrainment
|
Long-term potentiation
|
Glutamatergic synapse
|
Alzheimer's disease
|
Amyotrophic lateral sclerosis (ALS)
|
Huntington's disease
|
Cocaine addiction
|
Amphetamine addiction
|
Nicotine addiction
|
Alcoholismhsa04014:Ras signaling pathway
|
Dopaminergic synapse
|
Alcoholism
|
Systemic lupus erythematosushsa04014:Ras signaling pathway
|
Systemic lupus erythematosus
|
PANTHER Pathway
|
Huntington disease
|
Ionotropic glutamate receptor pathway
|
Metabotropic glutamate receptor group III pathway
|
Metabotropic glutamate receptor group I pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00029:Huntington disease
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
Pathway Interaction Database
|
ErbB4 signaling events
|
Reelin signaling pathwayreelinpathway:Reelin signaling pathway
|
Reactome
|
EPHB-mediated forward signaling
|
Unblocking of NMDA receptor, glutamate binding and activation
|
CREB phosphorylation through the activation of CaMKII
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
RAF/MAP kinase cascadeR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-3928662:EPHB-mediated forward signaling
|
RAF/MAP kinase cascadeR-HSA-438066:Unblocking of NMDA receptor, glutamate binding and activation
|
RAF/MAP kinase cascade
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Hypothetical Network for Drug Addiction
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
Spinal Cord Injury
|
BDNF signaling pathway
|
Alzheimers DiseaseWP80:Nucleotide GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
BDNF signaling pathwayWP666:Hypothetical Network for Drug Addiction
|
Alzheimers Disease
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2403). |
---|
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000713) |
---|
REF 3 | J Med Chem. 1995 Jun 23;38(13):2483-9.Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. |
---|
REF 4 | J Med Chem. 2005 Nov 3;48(22):6887-96.2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. |